JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB290829

Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein is a Fragment protein, in the 316 to 538 aa range, expressed in HEK 293 cells, with >85%, suitable for SDS-PAGE.
3 Images
SDS-PAGE - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (AB290829)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (AB290829)

SDS-PAGE analysis of ab290829 (3.5 μg).

Reducing conditions with Coomassie Blue staining.

Indirect ELISA - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (AB290829)
  • I-ELISA

Supplier Data

Indirect ELISA - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (AB290829)

Indirect ELISA showing primary antibody ab283913 binding SARS-CoV-2 (Omicron variant) Spike Glycoprotein S1 (ab290828); SARS-CoV-2 (Omicron variant) Spike Glycoprotein RBD (ab290829); Recombinant SARS-CoV-2 Omicron variant Spike protein (GCN4-IZ) His tag; Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera) (ab272106). Antigen concentration is 1000 ng/ml. Substrate solution is p-nitrophenyl phosphate(PNPP). Binding of ab283913 was assessed in a serial dilution range 1000-0 ng/ml. Binding was detected using the secondary antibody, Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at 1/2500 dilution.

Dot Blot - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (AB290829)
  • Dot

Lab

Dot Blot - Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (AB290829)

Dot blot analysis using ab283913 at 1/1000 dilution followed by a Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution. Lane 1 : Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 (ab290828). Lane 2 : Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein S1 RBD protein (ab290829). Lane 3 : Recombinant Human coronavirus SARS-CoV-2 (B.1.1.529/Omicron) Spike protein. Lane 4 : Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (ab272106). Blocking buffer and concentration : 5% NFDM/TBST. Diluting buffer and concentration : 5% NFDM/TBST. Exposure Time : 180 seconds.

Key facts

Purity

>85% SDS-PAGE

Expression system

HEK 293 cells

Tags

His tag C-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Animal free

Yes

Carrier free

Yes

Storage buffer

Constituents: DPBS

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Recombinant SARS-CoV-2 Omicron variant Spike receptor binding domain protein. Relative to Wuhan-Hu-1 this protein has following amino acid changes: G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H.
style
left-column

Sequence info

[{"sequence":"","proteinLength":"Fragment","predictedMolecularWeight":"27 kDa","actualMolecularWeight":"35 kDa","aminoAcidEnd":538,"aminoAcidStart":316,"nature":"Recombinant","expressionSystem":null,"accessionNumber":null,"tags":[{"tag":"His","terminus":"C-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike RBD also known commonly as the Receptor Binding Domain of the spike protein plays an important role in viral entry into host cells. This domain has a mass of approximately 21 kDa. It is located on the surface of the virus and facilitates binding to the host cell receptor primarily ACE2 which permits viral entry and replication. The Spike RBD is also a target for neutralizing antibodies which are essential in immune response against the virus. The domain displays various mutations particularly in variants of concern such as Omicron which can affect binding efficiency and immune evasion.
Biological function summary

The SARS-CoV-2 Spike RBD interacts directly with the host ACE2 receptor to mediate entry of the virus into host cells. This interaction is necessary for the virus to fuse with the host cell membrane which allows viral RNA to enter the host cell and begin replication. The Spike protein of which the RBD is a part forms a trimeric complex on the virus surface that is important for host interaction. Variations in the Spike RBD such as mutations like Arg319-Phe541 have significant impacts on the binding affinity to ACE2 and the effectiveness of vaccine-elicited antibodies.

Pathways

The Spike RBD of SARS-CoV-2 is vital in the entry pathway of the virus into the host cell. It is prominently involved in the ACE2-mediated signaling pathway with ACE2 playing the key role as the cellular receptor. This pathway is integral to the pathogenesis of COVID-19. Additionally the presence of the virus in host cells can trigger inflammatory pathways via infection-induced signaling cascades which can lead to exacerbated immune responses.

The SARS-CoV-2 Spike RBD is inherently linked to COVID-19 pathogenesis. Variants such as Omicron have alterations within the RBD that may confer increased transmissibility and resistance to neutralizing antibodies. These mutations can influence disease severity and vaccine effectiveness. The interaction between the Spike RBD and ACE2 receptor underlies the symptomatic manifestations of COVID-19 including respiratory distress and systemic inflammation. The emergence of RBD-targeted therapeutics and vaccines addresses its critical role in infection aiming to block the binding and prevent disease progression.
style
left-column

Specifications

Form

Liquid

Additional notes

Purified from tissue culture supernatant.

style
left-column

General info

style
left-column

Product protocols

style
left-column

Target data

See full target information SARS-CoV-2 Spike RBD
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB283943

Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - BSA and Azide free

RabMAb|Recombinant

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - BSA and Azide free (AB283943)

  • 0
  • 0
Proteins & Peptides

AB275986

Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein RBD (His tag)

Indirect ELISA - Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein RBD (His tag) (AB275986)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB271180

Rabbit monoclonal [EPR24334-118] to SARS-CoV-2 nucleocapsid protein

BOND RX™ Validated|20ul selling size|RabMAb|Recombinant

Flow Cytometry (Intracellular) - Rabbit monoclonal [EPR24334-118] to SARS-CoV-2 nucleocapsid protein (AB271180)

  • 5
  • 4

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com